Immediate Impact
1 by Nobel laureates 2 from Science/Nature 57 standout
Citing Papers
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
2024 Standout
Works of Robert Shumaker being referenced
A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma
2017
A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma.
2017
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Robert Shumaker | 211 | 83 | 119 | 97 | 18 | 530 | |
| David Lockley | 71 | 103 | 206 | 37 | 20 | 591 | |
| Tamiko Konishi | 198 | 197 | 62 | 30 | 15 | 598 | |
| James A. Bacon | 215 | 145 | 63 | 48 | 29 | 607 | |
| Jin Lin | 127 | 56 | 46 | 33 | 16 | 558 | |
| Onkar Singh | 100 | 90 | 88 | 60 | 44 | 592 | |
| Zirui Wan | 80 | 226 | 74 | 27 | 30 | 617 | |
| Ruth D. Davis | 89 | 103 | 103 | 14 | 14 | 473 | |
| Kiumars Vadiei | 89 | 117 | 50 | 61 | 26 | 575 | |
| Afaf A. Ain-Shoka | 59 | 141 | 84 | 31 | 20 | 533 | |
| B Booth | 170 | 86 | 35 | 66 | 17 | 520 |
All Works
Loading papers...